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The decision of moving therapy from HD imatinib to nilotinib in CML patients with 
resistance to standard dose imatinib is a reasonable option. 
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OBJECTIVES: While many new cancer treatments are expensive, their improved side 
effect proﬁ le may reduce overall costs to the health-care system compared to tradi-
tional chemotherapy. The objective of this work was to identify a benchmark 
approach to the estimation of costs for chemotherapy side effects, which could then 
be incorporated into estimates of overall chemotherapy costs. METHODS: A system-
atic review of clinical and economic literature was undertaken using multiple data-
bases and search terms for chemotherapy, adverse events, and cost. Eligible articles 
were reviewed for methods, quality and cost outcomes. Results were combined using 
descriptive techniques to identify best practice methodologies for estimating resource 
use and costs associated with managing chemotherapy side effects. RESULTS: From 
4985 titles, 59 eligible articles were identiﬁ ed. Studies were divided into model based 
analysis (n = 33) and empirical studies (n = 26). The perspectives, approaches, and 
methods for estimating quantities and value of resources consumed were highly vari-
able. These disparate methods contributed to highly divergent estimates of cost when 
speciﬁ c side effects were examined (eg $446 to $17,889 for neutropenia, 2009 AUD). 
A clear benchmark approach to the economic analysis of chemotherapy side effects 
was not available. Thus, general methodological recommendations were made to guide 
development of reliable, valid and transparent estimates of the costs of chemotherapy 
side effects, based on best practice modeling techniques. The recommendations address 
issues such as the use of 1) the health-care system perspective; 2) clinical guidelines 
and patterns of care studies to identify resources; 3) modeling and empirical methods 
to obtain accurate costing information; and 4) appropriate modeling to allow incor-
poration into broader economic evaluations. CONCLUSIONS: These recommenda-
tions provide a framework for developing cost estimates for speciﬁ c adverse events. 
The EMCaP Project will utilize this framework to incorporate estimates of adverse 
event costs into broader economic evaluations of alternative chemotherapy 
protocols. 
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OBJECTIVES: To validate the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire—C30 (EORTC QLQ-C30) in an Indonesian 
version. The standard procedure of forward-backward translation was adhered to in 
the translation procedures, pilot testing, review, and reliability and construct validity 
evaluation. METHODS: Data were collected from cancer patients in the Oncology 
Department of Dr. Sardjito Hospital, Yogyakarta, Indonesia, who were treated with 
a cisplatin at the dosage ≥50 mg/m2 as monotherapy or in combinations. We used the 
Short Form-36 (SF-36) to assess the construct validity of our translated questionnaire. 
RESULTS: About 85% patients (n = 17) were able to ﬁ ll out the questionnaires by 
themselves and there were no missing responses to the questions in the pilot study. 
One hundred twenty-eight patients with different cancer diagnoses were recruited in 
the validation process from March 2009 to November 2009. The internal consistency 
was above 0.70 for the SF-36 scales physical function, social function, pain, physical 
role, and emotional role; values >0.70 were observed in the Indonesian version of 
EORTC QLQ-C30 scales. Floor and ceiling effects were seen more evidently in the 
physical, social dimensions, pain and fatigue than in single items. Both of the question-
naires showed that different diagnoses were associated with a similar impact of quality 
of life in sensitivity tests. Correlations between Indonesian version of EORTC 
QLQ-C30 and SF-36 dimensions were moderate: between 0.18 and 0.48 for the ﬁ ve 
domains. The discriminant validity between the two questionnaires was acceptable 
(between 0.02–0.47). CONCLUSIONS: The Indonesian version of the EORTC QLQ 
C-30 can be used as a questionnaire to assess quality of life in Indonesian cancer 
patients. 
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OBJECTIVES: Compared with the 3- to 5-year coverage rates of 75% in many 
European countries, the 3-year coverage rate of 51.5% for Pap smear screening in 
Taiwan has not achieved a satisfactory level. Previous studies have showed that 
patients’ preferences were important information for improving the participation rate 
of cancer screening. This study aimed to understand women’s preferences for cervical 
cancer (CC) screening tests with various features. METHODS: Face-to-face patient 
interviews were carried out with 212 women aged 30–55 at the gynecological outpa-
tient clinics in a regional hospital in Taipei, Taiwan, during January and April 2009. 
The participants were asked to rate 12 pairs of hypothetical test scenarios comprised 
of different combinations of six attributes including accuracy of the test, price, screen-
ing administers, place of screening and frequency of screening. The relative importance 
of test attributes was calculated and a cluster analysis was done to identify subgroup 
with differential preferences. RESULTS: Accuracy, price, and place of screening (P < 
0.001) were found to be the most important attributes in determining women’s prefer-
ences. Cluster analysis revealed no signiﬁ cant differences in subgroup of women with 
different health-promoting lifestyles. CONCLUSIONS: The most preferred screening 
programs was “not screening at home,” “high accuracy of test,” and “low price” 
among women residing in a metropolitan city like Taipei. Future direction of study 
on preferences for CC screening should be targeted at women with low utilization of 
Paps smear screening to better inform the decision-makers in designing more effective 
CC prevention program. 
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OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for lung cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for lung cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with lung cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for lung cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁ gure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂ ecting ranges of 261 KRW~286 KRW and 3414 KRW~4538 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married and younger respondents, with higher income and education have more 
MWTP compared to their respective counterparts. One interesting point is that depen-
dents’ MWTP of survival rate is higher than that of insurance premium payers 
although MTWP of total treatment costs for dependents is signiﬁ cantly lower than 
premium payers’ MWTP. 
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OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for stomach cancer treatment and investigates the attributes affecting 
the respondents’ choice. Also it ascertains marginal willingness to pay and relative 
preferences for stomach cancer treatment among the general population of 600 respon-
dents in Korea. METHODS: In the survey, the respondents are asked to choose more 
than one discrete choice option, resulting in multiple observations for each individual. 
For each pair-wise comparison of choice set, the respondent will make a choice among 
three alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum 
likelihood allows us to empirically estimate multi-levels of dependent variables. For 
the robustness check of our empirical results, we try considering the nature of distribu-
tion of error terms in the utility function in several ways. The survey questionnaire 
includes four attributes associated with stomach cancer in Korea (incidence rates, 
survival rates in 5 years after treatment, total treatment costs, and monthly insurance 
premium), socio-economic status, antecedent variables, along with questions regarding 
risk averseness and subjective health evaluation. RESULTS: The estimates of MWTP 
between survival rate and monthly insurance premium and MTWP between total 
treatment costs and monthly insurance premium, by employing “Hybrid Conditional 
Fixed Effects Logit Model” to ﬁ gure out the existence of heterogeneity of any observed 
and unobserved components, are reﬂ ecting reasonable range of 176 KRW~194 KRW 
and 5408 KRW~6945 KRW, respectively. CONCLUSIONS: Compared to female 
counterparts, male respondents have higher MWTP of monthly insurance premium 
for two related attributes. Besides, currently married respondents, with higher income, 
and higher educational attainments have more MWTP compared to their respective 
counterparts. One interesting point is that dependents’ MWTP is higher than that of 
insurance premium payers even after controlling for any other variables. 
